.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Find suppliers and generic API sources
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Cantor Fitzgerald
Daiichi Sankyo
US Army
Cipla
Covington
Medtronic
Cerilliant
Dow
Boehringer Ingelheim

Generated: July 22, 2017

DrugPatentWatch Database Preview

Ani Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for ANI PHARMS INC, and when can generic versions of ANI PHARMS INC drugs launch?

ANI PHARMS INC has one hundred and twenty-one approved drugs.

There is one US patent protecting ANI PHARMS INC drugs.

There are fourteen patent family members on ANI PHARMS INC drugs in eleven countries.

Summary for Applicant: Ani Pharms Inc

Patents:1
Tradenames:63
Ingredients:59
NDAs:121
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ani Pharms Inc
PERPHENAZINE
perphenazine
TABLET;ORAL089457-001Sep 10, 1987DISCNNoNo► Subscribe► Subscribe
Ani Pharms Inc
DEXCHLORPHENIRAMINE MALEATE
dexchlorpheniramine maleate
TABLET;ORAL088682-001Jan 17, 1986DISCNNoNo► Subscribe► Subscribe
Ani Pharms Inc
DESIPRAMINE HYDROCHLORIDE
desipramine hydrochloride
TABLET;ORAL071803-004Dec 8, 1987RXNoNo► Subscribe► Subscribe
Ani Pharms Inc
TESTOSTERONE
testosterone
GEL;TRANSDERMAL202763-001Feb 14, 2012BXRXNoNo► Subscribe► Subscribe
Ani Pharms Inc
ETODOLAC
etodolac
CAPSULE;ORAL075126-002Sep 16, 1999ABRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Ani Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ani Pharms Inc
BRETHINE
terbutaline sulfate
TABLET;ORAL017849-002Approved Prior to Jan 1, 19824,011,258► Subscribe
Ani Pharms Inc
INDERAL LA
propranolol hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL018553-004Mar 18, 19874,138,475► Subscribe
Ani Pharms Inc
LITHOBID
lithium carbonate
TABLET, EXTENDED RELEASE;ORAL018027-001Approved Prior to Jan 1, 19824,264,573► Subscribe
Ani Pharms Inc
INDERAL LA
propranolol hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL018553-002Apr 19, 19834,138,475► Subscribe
Ani Pharms Inc
BRETHINE
terbutaline sulfate
TABLET;ORAL017849-001Approved Prior to Jan 1, 19824,011,258► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Ani Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,040,086Timed, sustained release systems for propranolol► Subscribe
9,358,214Timed, sustained release systems for propranolol► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ani Pharms Inc Drugs

Country Document Number Estimated Expiration
Spain2333306► Subscribe
MexicoPA04003234► Subscribe
Norway20041740► Subscribe
South Korea101090719► Subscribe
Germany60233668► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Ani Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0443983/03Switzerland► SubscribePRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009
292Luxembourg► SubscribePRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
C0008Belgium► SubscribePRODUCT NAME: RISPERIDONE; NAT REG.: 2 S 414 F 3 19940527; FIRST REG.: GB 0242/0186 19921208
C0005Belgium► SubscribePRODUCT NAME: FOSPHENYTOIN DISODIUM; NAT. REGISTRATION NO/DATE: NL 23 613 19980806; FIRST REGISTRATION: GB - PL 000 19/0157 19980204
14/008Ireland► SubscribePRODUCT NAME: DEXLANSOPRAZOLE OR A SALT THEREOF; NAT REGISTRATION NO/DATE: PA1864/001/001-002;PA1864/002/001-002 20131125; FIRST REGISTRATION NO/DATE: 47911 47912 47913 47914 20130919
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Citi
Cantor Fitzgerald
McKinsey
Julphar
Chinese Patent Office
US Army
Johnson and Johnson
QuintilesIMS
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot